Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)

Core Insights - Autonomix Medical, Inc. announced that an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO) [1] Company Overview - Autonomix is a medical device company focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system [4] - The company's first-in-class platform technology includes a catheter-based microchip sensing array that can detect and differentiate neural signals with up to 3,000 times greater sensitivity than current technologies [4] - The initial development of this technology targets pain management, specifically for pancreatic cancer, which is known for causing severe pain and lacks reliable treatment options [5] - The technology has potential applications across various indications, including cardiology, hypertension, and chronic pain management [5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5] Event Details - The poster presentation at ECIO 2025 is titled "Catheter-Based Transvascular RF Neural Ablation for Severe Pancreatic Cancer Pain: First Results from The Elpis Study" [2] - The conference is recognized as a comprehensive platform for interventional oncology education, featuring over 140 lectures and 16 hands-on training sessions [2]